Cytogenetic and clinical risk factors for assessment of ultra high-risk multiple myeloma.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis

• Publication date

  2014-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.leukres.2013.11.010PMID 24342807
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• [Observation of humoral immunity reconstitution and its relationship with infection after autologous hematopoietic stem cell transplantation for patients with multiple myeloma].

  2013cited by this paper
• Multiple myeloma: 2012 update on diagnosis, risk‐stratification, and management

  2012cited by this paper
• Multiple myeloma: treatment evolution

  2012cited by this paper
• IgD multiple myeloma a descriptive report of 17 cases: survival and response to therapy

  2012cited by this paper
• Complex karyotype and translocation t(4;14) define patients with high-risk newly diagnosed multiple myeloma: results of CMG2002 trial

  2012cited by this paper
• Bortezomib, liposomal doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective treatment for patients with newly diagnosed multiple myeloma with Internatinal Staging System stage II or III, or extramedullary disease

  2012cited by this paper
• Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p.

  2012cited by this paper
• Update on risk stratification and treatment of newly diagnosed multiple myeloma

  2011cited by this paper
• Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2.

  2011cited by this paper
• International staging system and metaphase cytogenetic abnormalities in the era of gene expression profiling data in multiple myeloma treated with total therapy 2 and 3 protocols

  2011cited by this paper
• Chromosomal aberrations +1q21 and del(17p13) predict survival in patients with recurrent multiple myeloma treated with lenalidomide and dexamethasone

  2011cited by this paper
• A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial

  2011cited by this paper
• Increased serum lactate dehydrongenase should be included among the variables that define very-high-risk multiple myeloma.

  2011cited by this paper
• Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p).

  2010cited by this paper
• Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantation

  2010cited by this paper
• Ultra high-risk myeloma.

  2010cited by this paper
• Review of phenotypic markers used in flow cytometric analysis of MGUS and MM, and applicability of flow cytometry in other plasma cell disorders

  2010cited by this paper
• Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicin-dexamethasone in multiple myeloma: results of a phase II study.

  2010cited by this paper
• Evidence for cytogenetic and fluorescence in situ hybridization risk stratification of newly diagnosed multiple myeloma in the era of novel therapie.

  2010cited by this paper
• VMP (Bortezomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA study.

  2009cited by this paper
• Autologous hematopoietic stem-cell transplantation for multiple myeloma.

  2009cited by this paper
• Multiple myeloma

  2009cited by this paper
• Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13.

  2009cited by this paper
• Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: a study of the Intergroupe Francophone du Myélome.

  2008cited by this paper
• Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation.

  2008cited by this paper
• Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement.

  2007cited by this paper
• From bloodjournal.hematologylibrary.org at PENN STATE UNIVERSITY on February 21, 2013. For personal use only.

  2007cited by this paper
• Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials

  2007cited by this paper
• Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome.

  2007cited by this paper
• CKS1B, overexpressed in aggressive disease, regulates multiple myeloma growth and survival through SKP2- and p27Kip1-dependent and -independent mechanisms.

  2007cited by this paper
• Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation.

  2006cited by this paper
• Prevalence of monoclonal gammopathy of undetermined significance.

  2006cited by this paper
• Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib.

  2006cited by this paper
• A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1.

  2006cited by this paper
• International staging system for multiple myeloma.

  2005cited by this paper
• Overexpression of PDZK1 within the 1q12-q22 amplicon is likely to be associated with drug-resistance phenotype in multiple myeloma.

  2004cited by this paper
• Clinical and biologic implications of recurrent genomic aberrations in myeloma.

  2003cited by this paper
• Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group

  2003cited by this paper
• Chromosome 13 abnormalities identified by FISH analysis and serum beta2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy.

  2001cited by this paper
• [A clinical analysis of 798 cases of M protein positive patients].

  2001cited by this paper
• Elevated soluble MUC1 levels and decreased anti-MUC1 antibody levels in patients with multiple myeloma.

  2000cited by this paper
• Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy.

  1998cited by this paper
• p53 gene mutations in multiple myeloma are associated with advanced forms of malignancy.

  1993cited by this paper
• p53 gene mutations in multiple myeloma are associated with advanced forms of malignancy

  1993cited by this paper
• Analysis of 128 cases of multiple myeloma and 31 cases of monoclonal gammapathies of undetermined significance

  1989cited by this paper
• [Analysis of 128 cases of multiple myeloma and 31 cases of monoclonal gammapathies of undetermined significance].

  1989cited by this paper

• RUNX1 expression dynamics in plasma cell differentiation and pathogenesis of multiple myeloma

  2025cites this paper
• Chromosome 1q21 Aberrations Are Poor Prognostic Factors for Newly Diagnosed Multiple Myeloma Patients

  2024cites this paper
• Characteristics and Risk Factors of Ultra-High-Risk Patients with Newly Diagnosed Multiple Myeloma

  2023cites this paper
• Factores pronósticos que afectan la supervivencia en el paciente con mieloma múltiple

  2021cites this paper
• The combination of C-Myc rearrangement and 1q21 gain is associated with poor prognosis in multiple myeloma

  2021cites this paper
• Primary refractory multiple myeloma: a real-world experience with 85 cases

  2020cites this paper
• Clinical relevance of PET/CT in patients with newly diagnosed multiple myeloma.

  2019cites this paper
• Clinical characteristics and prognosis of multiple myeloma with bone-related extramedullary disease at diagnosis

  2018cites this paper
• Plasma Cell Leukemia and Extramedullary Plasmacytoma

  2018cites this paper
• Primary failure of bortezomib in newly diagnosed multiple myeloma – understanding the magnitude, predictors, and significance

  2016cites this paper
• Conventional and Molecular Cytogenetics in Plasma Cell Neoplasms

  2016cites this paper
• Clinical characteristics of patients with relapsed multiple myeloma.

  2015cites this paper
• [Clinical analysis of multiple myeloma patients with bone-related extramedullary disease: a longitudinal study on 834 consecutive patients in a single center of China].

  2015cites this paper
• LDH is an adverse prognostic factor independent of ISS in transplant‐eligible myeloma patients receiving bortezomib‐based induction regimens

  2015cites this paper
• Szpiczak plazmocytowy wysokiego ryzyka

  2015influential citation
• MECHANISMS OF DRUG-ESCAPE AND RELAPSE IN MULTIPLE MYELOMA: INTERPLAY BETWEEN ADAR1 AND NOTCH IN ABERRANT RNA EDITING

  2015cites this paper
• Survival Analysis of Total Therapy 3 in Newly Diagnosed Multiple Myeloma

  2015cites this paper
• 多发性骨髓瘤伴单纯骨旁髓外病变临床分析——单中心连续性834例患者资料研究

  2015cites this paper
• Limited value of the international staging system for predicting long-term outcome of transplant-ineligible, newly diagnosed, symptomatic multiple myeloma in the era of novel agents

  2014cites this paper